Multi-institute randomized study of natural type interferon alpha for patients with renal cell carcinoma after radical nephrectomy

Multi-institute randomized study of natural type interferon alpha for patients with renal cell carcinoma after radical nephrectomy - Trial of RCC adjuvant interferon alpha (TRAIn-Alpha)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000256

Enrollment

540

Registered

2005-09-30

Start date

2001-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma

Interventions

Administration of natural type interferon alpha for at least one year Observation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically confirmed RCC After radical nephrectomy Stage II or III Performance Status 0 to 2 WBC count 3500 or over PLT count 100000 or over AST, ALT within 2.5 times of institute reference level Creatinine 2.0mg/dl or less Total bilirubin within 1.5 times of institute reference level Written informed consented No prior chemotherapy nor immuno- therapy

Exclusion criteria

Exclusion criteria: Active synchronous malignancy Bellini duct carcinoma von Hippel-Lindau disease History of allergy for interferon or vaccine

Design outcomes

Primary

Measure	Time frame
Local recurrence and distant metastasis	—

Countries

Japan

Contacts

Public ContactHideyuki Akaza MD

University of Tsukuba Department of Urology

029-853-3223

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026